Atea Pharmaceuticals Analyst Ratings
Atea Pharmaceuticals Analyst Ratings
Atea Pharmicals
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 01/24/2023 | -15.79% | Morgan Stanley | $7 → $4 | Maintains | Underweight |
| 08/15/2022 | 47.37% | Morgan Stanley | $6 → $7 | Maintains | Underweight |
| 03/02/2022 | 68.42% | JP Morgan | $10 → $8 | Maintains | Neutral |
| 03/01/2022 | 89.47% | SVB Leerink | $10 → $9 | Maintains | Market Perform |
| 02/16/2022 | 110.53% | SVB Leerink | $11 → $10 | Maintains | Market Perform |
| 01/06/2022 | 47.37% | Morgan Stanley | $14 → $7 | Downgrades | Equal-Weight → Underweight |
| 11/18/2021 | 131.58% | SVB Leerink | → $11 | Downgrades | Outperform → Market Perform |
| 10/20/2021 | 321.05% | SVB Leerink | $60 → $20 | Maintains | Outperform |
| 10/20/2021 | 236.84% | JP Morgan | $61 → $16 | Downgrades | Overweight → Neutral |
| 10/05/2021 | 1057.89% | Morgan Stanley | → $55 | Downgrades | Overweight → Equal-Weight |
| 09/09/2021 | 1163.16% | SVB Leerink | → $60 | Initiates Coverage On | → Outperform |
| 08/18/2021 | 678.95% | Morgan Stanley | $35 → $37 | Maintains | Overweight |
| 06/03/2021 | 636.84% | Morgan Stanley | $82 → $35 | Maintains | Overweight |
| 04/06/2021 | 1626.32% | Morgan Stanley | $49 → $82 | Maintains | Overweight |
| 01/29/2021 | 1289.47% | JP Morgan | $45 → $66 | Maintains | Overweight |
| 11/25/2020 | — | Evercore ISI Group | Initiates Coverage On | → Outperform | |
| 11/24/2020 | 847.37% | JP Morgan | → $45 | Initiates Coverage On | → Overweight |
| 11/24/2020 | — | William Blair | Initiates Coverage On | → Outperform | |
| 11/24/2020 | 931.58% | Morgan Stanley | → $49 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 01/24/2023 | -15.79% | 摩根士丹利 | $7→$4 | 维护 | 体重不足 |
| 2022年08月15日 | 47.37% | 摩根士丹利 | $6→$7 | 维护 | 体重不足 |
| 03/02/2022 | 68.42% | 摩根大通 | $10→$8 | 维护 | 中性 |
| 03/01/2022 | 89.47% | SVB Leerink | $10→$9 | 维护 | 市场表现 |
| 02/16/2022 | 110.53% | SVB Leerink | $11→$10 | 维护 | 市场表现 |
| 01/06/2022 | 47.37% | 摩根士丹利 | $14→$7 | 评级下调 | 等重→减码 |
| 2021年11月18日 | 131.58% | SVB Leerink | →$11 | 评级下调 | 跑赢→市场表现 |
| 10/20/2021 | 321.05% | SVB Leerink | $60→$20 | 维护 | 跑赢大盘 |
| 10/20/2021 | 236.84% | 摩根大通 | $61→$16 | 评级下调 | 超重→中性 |
| 10/05/2021 | 1057.89% | 摩根士丹利 | →$55 | 评级下调 | 超重→等重 |
| 09/09/2021 | 1163.16% | SVB Leerink | →$60 | 开始承保 | →跑赢大盘 |
| 2021/08/18 | 678.95% | 摩根士丹利 | $35→$37 | 维护 | 超重 |
| 06/03/2021 | 636.84% | 摩根士丹利 | $82→$35 | 维护 | 超重 |
| 04/06/2021 | 1626.32% | 摩根士丹利 | $49→$82 | 维护 | 超重 |
| 2021/01/29 | 1289.47% | 摩根大通 | $45→$66 | 维护 | 超重 |
| 11/25/2020 | - | Evercore ISI集团 | 开始承保 | →跑赢大盘 | |
| 11/24/2020 | 847.37% | 摩根大通 | →$45 | 开始承保 | →超重 |
| 11/24/2020 | - | 威廉·布莱尔 | 开始承保 | →跑赢大盘 | |
| 11/24/2020 | 931.58% | 摩根士丹利 | →$49 | 开始承保 | →超重 |
What is the target price for Atea Pharmaceuticals (AVIR)?
ATEA制药(Avir)的目标价是多少？
There is no price target for Atea Pharmaceuticals
ATEA制药公司没有目标价格
What is the most recent analyst rating for Atea Pharmaceuticals (AVIR)?
分析师对安泰制药(AVIR)的最新评级是多少？
There is no analyst for Atea Pharmaceuticals
ATEA制药公司没有分析师
When is the next analyst rating going to be posted or updated for Atea Pharmaceuticals (AVIR)?
安泰制药(Avir)的下一次分析师评级将于何时发布或更新？
There is no next analyst rating for Atea Pharmaceuticals
没有下一个分析师对ATEA制药的评级
Is the Analyst Rating Atea Pharmaceuticals (AVIR) correct?
分析师对安泰制药(AVIR)的评级正确吗？
There is no next analyst rating for Atea Pharmaceuticals
没有下一个分析师对ATEA制药的评级